Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study
- Conditions
- Cardiogenic Shock
- Registration Number
- NCT03346824
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
Failure of Weaning from ECMO is a serious complication, reaching an incidence between 29 and 58%. Inotrops are frequently used to help separating patient from ECMO. Levosimendan is an ino-dilatatory medication and was used in different clinical settings. The aim of this study was to evaluate the benefit with levosimendan when used in weaning process.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
- Age over 18
- Patient requiring the need for short-term assistance
- Patient who has agreed to use his medical data for research purposes
Exclusion Criteria
- Refusal to participate in the study
- Non-weaning attempts due to a death under assistance or a relay by a long-term assistance or heart transplant
- Non-cardiac indications of assistance (indication of pulmonary replacement)
- Subject under guardianship or curatorship
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of the incidence of weaning failure between patients with levosimendan and others Data were recorded from admission until 48 hours after weaning from ECMO
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Service Réanimation chirurgicale cardiovasculaire-NHC
🇫🇷Strasbourg, France